Delcath Systems' HEPZATO KIT Gains NCCN Recognition for Metastatic Uveal Melanoma Treatment
- Delcath Systems’ HEPZATO KIT is now a Category 2A treatment for hepatic-dominant metastatic uveal melanoma, broadening patient options.
- The HEPZATO KIT delivers high-dose chemotherapy directly to the liver, minimizing systemic side effects and enhancing patient outcomes.
- Delcath's recognition by NCCN emphasizes its commitment to innovative solutions for liver cancer and may increase product demand.
Delcath Systems Expands Treatment Options for Metastatic Uveal Melanoma
Delcath Systems, Inc. announces a significant milestone in its ongoing commitment to interventional oncology for liver cancers with the recent update from the National Comprehensive Cancer Network (NCCN). The NCCN has included the HEPZATO KIT™ as a Category 2A treatment option for patients suffering from hepatic-dominant metastatic uveal melanoma (mUM). This pivotal change broadens the previous recommendation, which only encompassed patients with liver-confined metastases. With over 90% of mUM patients likely to develop liver metastases, this update is crucial in enhancing treatment pathways for a larger subset of patients grappling with this aggressive form of cancer.
The inclusion of the HEPZATO KIT in the NCCN guidelines underlines the significant role that hepatic progression plays in the overall disease trajectory of metastatic uveal melanoma. Delcath’s HEPZATO KIT, which utilizes a specialized Hepatic Delivery System (HDS) to administer high-dose chemotherapy directly to the liver, minimizes systemic exposure and associated side effects. This localized delivery method is designed to improve patient outcomes and potentially lead to more significant tumor responses. The recent subgroup analysis from the Phase 3 FOCUS trial reinforces the efficacy of this treatment approach, showing no substantial differences in response rates or survival outcomes between patients with and without extrahepatic disease.
Gerard Michel, CEO of Delcath, expresses optimism about the NCCN’s revised guidelines, noting that this recognition aligns with the company’s mission to provide innovative solutions for patients facing challenging cancers. The expanded endorsement of the HEPZATO KIT not only validates Delcath’s commitment to advancing treatment options for liver cancer but also emphasizes the growing consensus on the importance of addressing hepatic metastases in the management of metastatic uveal melanoma. By incorporating HEPZATO into established treatment frameworks, Delcath is poised to make a meaningful impact on patient care in this area.
In addition to this update, the recognition from NCCN marks a step forward in the integration of targeted therapies within oncology practice. As more clinicians adopt the HEPZATO KIT for their patients, Delcath Systems may see an increase in demand for its innovative products. This change indicates a shifting landscape in the treatment of liver cancers, highlighting the need for specialized solutions that address the complexities of hepatic disease progression.
Overall, Delcath’s advancements in interventional oncology signify a promising direction for the treatment of metastatic uveal melanoma, offering hope for patients facing this challenging diagnosis.